Hippocampal pathology occurs early in Alzheimer disease (AD), and atrophy, measured by volumes and volume changes, may predict which subjects will develop AD. Measures of the temporal horn (TH), which is situated adjacent to the hippocampus, may also indicate early changes in AD. Previous studies suggest that these metrics can predict conversion from amnestic mild cognitive impairment (MCI) to AD with conversion and volume change measured concurrently. However, the ability of these metrics to predict future conversion has not been investigated. We compared the abilities of hippocampal, TH, and global measures to predict future conversion from MCI to AD. TH, hippocampi, whole brain, and ventricles were measured using baseline and 12-month scans. Boundary shift integral was used to measure the rate of change. We investigated the prediction of conversion between 12 and 24 months in subjects classified as MCI from baseline to 12 months. All measures were predictive of future conversion. Local and global rates of change were similarly predictive of conversion. There was evidence that the TH expansion rate is more predictive than the hippocampal atrophy rate (P=0.023) and that the TH expansion rate is more predictive than the TH volume (P=0.036). Prodromal atrophy rates may be useful predictors of future conversion to sporadic AD from amnestic MCI.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154837PMC
http://dx.doi.org/10.1097/WAD.0b013e318260a79aDOI Listing

Publication Analysis

Top Keywords

future conversion
20
conversion
9
temporal horn
8
rates change
8
metrics predict
8
predict future
8
expansion rate
8
rate predictive
8
future
5
hippocampal
4

Similar Publications

Background: Alzheimer's disease (AD) is pathologically defined by the presence of extracellular Aβ plaque and intracellular tau inclusions. Emerging evidence shows that tau aggregates contain pathogenic bioactivities of templating monomeric tau into filamentous fibrils and propagating through cells. Based on these findings, assays have been developed to detect minute amounts of pathogenic tau in human samples.

View Article and Find Full Text PDF

Background: Subjective cognitive decline (SCD) is recognized to be in the Alzheimer's disease (AD) cognitive continuum. An international working group known as the SCD-initiative recently proposed "SCD plus" features, including report of memory problems, recent SCD relative to conversion, SCD over age 60, and consistent SCD over time, that increase the risk for future objective cognitive decline. These have not been fully assessed in a large community-based setting.

View Article and Find Full Text PDF

Clinical Manifestations.

Alzheimers Dement

December 2024

Stanford University, Stanford, CA, USA.

Historically, screening for incidence of AD-related MCI or conversion from MCI to AD dementia has relied on cognitive, activities of daily living, and brain imaging measures. Limitations of this diagnostic approach include dependency on education and language, time-consuming and costly measures, and long-term monitoring. Emerging studies suggest that non-tremor motor dysfunction in dementias is known to be highly associated with AD biomarkers, with signs of cognitive decline visible in gait and hand movement at various stages of the illness.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.

Background: For large genomic studies of middle-aged individuals, the prevalence of Alzheimer's disease (AD) is extremely low, making it difficult to conduct genomic analysis of the condition. To enable genome-wide association studies of AD in such datasets, an approach called Genome-wide association by proxy (GWAX) uses family history of disease as a proxy for disease status. Borrowing from the machine learning (ML) literature, we treat the development of proxy phenotypes as a pseudo-labelling task, where an ideal proxy label accurately predicts the lifetime risk of AD.

View Article and Find Full Text PDF

This perspective highlights the transformative potential of Metal-Organic Frameworks (MOFs) in environmental and healthcare sectors. It discusses work that has advanced beyond technology readiness levels of >4 including applications in capture, storage, and conversion of gases to value added products. This work showcases efforts in the most salient applications of MOFs which have been performed at a great cadence, enabled by the federal government, large companies, and startups to commercialize these technologies despite facing significant challenges.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!